We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Byotrol Plc | LSE:BYOT | London | Ordinary Share | GB00B0999995 | ORDS 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.10 | 0.05 | 0.15 | 0.10 | 0.10 | 0.10 | 4,650,771 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Chemicals & Chem Preps, Nec | 4.59M | -1.69M | -0.0037 | -0.27 | 453.89k |
Date | Subject | Author | Discuss |
---|---|---|---|
22/7/2020 09:04 | While you can’t rule out the possibility of someone offering “silly” money as a buyout price, particularly if it involves much-higher rated paper (such as TSTL shares), it seems to me too early to think seriously about a sale of the company. There’s too much still to deliver and to get into the market perception for the starting point of the current company market cap to provide a sensible base for negotiations. Things that come to mind are: - More licence deals to do; - Sort out the supply chain so that the market can have confidence that supply is there for byotrol’s own product sales to feed demand growth; - Get the guaranteed future cash payments element of existing licence deals onto the balance sheet (contract assets) and understood by the market; - Allow time for actual royalty payments to start coming through in excess of the guaranteed minimum payments, so the market can start to build in this future very high margin revenue stream. | 1gw | |
22/7/2020 08:46 | I don`t want a cheap buy either and would prefer a bigger, more profitable company but markets are not like that and a really good offer would tempt many to sell now. | arcadian | |
22/7/2020 08:41 | That's a nice early shareprice move. Is that rimau1 (& others?) switching some out of TSTL? | 1gw | |
22/7/2020 08:02 | I don't think anyone on the byotrol side will be encouraging a "cheap purchase". Tristel has a high rating in part because of its long and steady track record on the financials, as was demonstrated by the charts someone put on this board a while back. Byotrol has a chance now to build a track record which will in due course be rewarded by a higher rating. The first step is to get some better visibility on 1H and full year revenue and earnings expectations. The £10m revs / £2m pbt [edit: and in the finnCap note it's £0.7m adj PBT for FY21 isn't it?] feel fairly flaky numbers at the moment and the next company update should make the estimates for this year, and particularly for 1H, a lot more solid. | 1gw | |
22/7/2020 07:59 | Tristel ahead of market expectations.. Byot didn't meet expectations.. Huge difference Read the company newsflow | sikhthetech | |
22/7/2020 07:53 | They would be stupid not to take advantage of those facts by a cheap purchase. | arcadian | |
22/7/2020 07:52 | Agree loaf either one has to go down or the other UP | riddlerone | |
22/7/2020 07:48 | From the update "Tristel medical device decontamination products accounted for 80% of global sales in the eight-month period to 28 February 2020. These products are principally used for diagnostic purposes in hospital departments such as ear, nose and throat, obstetrics and gynaecology, cardiology, urology, and ophthalmology. The Company's hospital surface disinfection products have historically been the less significant element of its product mix, albeit that the global hospital surface disinfection market is far greater in value terms than the global medical device decontamination market. The Company's hospital surface disinfection products accounted for 9% of global sales in the eight months to the end of February. Commencing in March, the Company experienced two powerful countervailing forces: 1) a decline in the use of its medical device decontamination products as hospitals worldwide postponed all but the most critical patient appointments to free up resources to deal with COVID-19 related cases, and 2) a surge in purchasing and use of its hospital surface disinfection products. During the last four months of the year, when the impact of COVID-19 was at its greatest, global sales were GBP11.8m compared to GBP9.1m in the same period last financial year, an increase of 30%. Medical device decontamination product sales accounted for 61% of global sales in this period, whilst sales of hospital surface disinfection products accounted for 27%. Tristel estimates that COVID-19 resulted in a temporary reduction of GBP0.5m in medical device decontamination product sales and an increase in sales of hospital surface disinfection products of GBP2m above the underlying trend. As can be seen, Tristel was able to navigate its way through the COVID-19 crisis by mitigating the fall in demand for its primary product portfolio by a rapid increase in supply of its hospital surface disinfection products". So the key areas that we and our partners operate in have been surging | riddlerone | |
22/7/2020 07:48 | Tris have a £200m mcap on £30 revs and £6m pbt. Byot have a £25m mcap on £10 revs and £2m pbt? Looks a bit unfair? | loafofbread | |
22/7/2020 07:31 | They've done well, especially in hospital surface disinfection with the Cache range of products. Not clear how much (if any) of the two byotrol formulation products is included in those sales, but the customer acquisition they refer to for the Cache brand should create a strong pull going forward. | 1gw | |
22/7/2020 07:29 | Surface decontamination by "approved" products to the fore. I didn`t see a mention of Byotrol but their products are the growth area. Wouldn`t surprise me if they bid for us. Byotrol has the products and the approvals. | arcadian | |
22/7/2020 07:19 | tristel TU today | football | |
22/7/2020 07:06 | Do you mean that the slowdown of sales flagged by company from record levels is in the price as tha5 is wha5 the company disclosed, and if in fact sales remain very high the shares are undervalued? | the ghost who walks | |
21/7/2020 22:41 | Https://www.allabout | football | |
21/7/2020 22:28 | BYOT is going up, so just get back into your padded cell and shut your noise. | a.fewbob | |
21/7/2020 22:25 | best1467 "with the new EU regularly changes on the way which should eliminate a number of the completion" I assume you mean 'Competition'...;-) Who are these competitors that you claim will be eliminated? What about no deal Brexit? How would that affect Byot and their competition? | sikhthetech | |
21/7/2020 22:24 | The guy obviously has a loose screw. A complete fruit loop. | a.fewbob | |
21/7/2020 21:57 | Regularity | best1467 | |
21/7/2020 21:55 | One thing I can guarantee is when I occasionally visit this thread I am reassured by the regular negative repetitive posts from SKH. Tristel Numbers will be interesting I would imagine they have taken a big hit with ENAT departments been closed for 3 months or more but as Covid factor made up the difference I’m relaxed as the long term outlook is for continued double digit growth and theFDA news must be Getting close. As for BYOT they could well achieve stronger growth over the next number of years with the new EU regularly changes on the way which should eliminate a number of the completion. | best1467 | |
21/7/2020 21:11 | STT must be the only person that covid19 as not had any effective on as when he is wearing a mask it won't stop him from talking out of his ass | football | |
21/7/2020 19:14 | Good little company but DT needs to polish his water cooler pitch. Hesitations and minor stumbles can be interpreted as low in confidence Good points profitable to March this year. AND This year a bumper year by implication. Also transformative to the business. | tonsil | |
21/7/2020 19:07 | Video but no sales update from company... one week ago The last update was 2 months ago and nothing for June/July.. Therefore, I think the next update maybe the results, usually around Aug/Sept.. Byot provided a TU every month since the lockdown...on 23/03, 27/04 & 14/05. Without an update, I suspect there's no change since the last update and orders have slowed down as they previously indicated. The May update FROM THE COMPANY: Record levels in the 1st QTR, ie to June... then optimistic of high levels, not record levels for remainder of H1... "As we start a new financial year, we are pleased to report that sales momentum remains strong. We expect to generate record sales in the first quarter of the year and are optimistic that high levels of demand will continue for the remainder of the first half at least. Sales in March and April 2020 each exceeded GBP1m and we are expecting to show similarly strong performance in May. Our order book at the end of April stood at over GBP2m. The Group's supply chain is working well despite the global shortage of biocidal ingredients, exacerbated by unpredictable national lockdowns and border closures." EVERYONE SHOULD READ THE COMPANY NEWSFLOW and form their own opinion. | sikhthetech | |
21/7/2020 18:09 | Still looks very good here. Happy holder | the ghost who walks | |
21/7/2020 17:05 | HTtps://vimeo.com/43 | football |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions